Medical intelligence platform Lynx.MD has announced a partnership with Prometheus Laboratories Inc. (“Prometheus”) and Gastro Health, to securely unite real-world clinical data for retrospective analysis of inflammatory bowel disease (IBD) biologic treatment.
Gastro Health is one of the largest gastroenterology practices in the U.S, it will provide access to a real-world data repository of over 3 million unique patients from more than 375 GI physicians, making it one of the largest real-world data sets for IBD. The Lynx.MD platform allows researchers to work with both structured and unstructured real-world patient data. The platform enables researchers to combine real-world clinical data from healthcare provider organisations with their own datasets, to allow for a more comprehensive understanding of patients outcomes.
The partnership will use Lynx Trusted Data Environment to bring together 10 years of de-identified IBD clinical laboratory data and patient data, to research and demonstrate the value of the Prometheus Anser IFX therapeutic drug monitoring test to improve patient clinical outcomes and reduce overall healthcare costs in IBD patient management.
"Our partnership with Lynx.MD and Gastro Health enable us to access one of the largest IBD real-world data repositories available," said Patricia Vasquez, Senior Vice President, Commercial and Corporate Development at Prometheus Laboratories. "We believe that the ability to securely combine de-identified clinical laboratory data with an extensive repository of clinical practice data will allow us to gain valuable insights into the real-world clinical utility of Anser IFX as a precision medicine tool and its effectiveness in improving patient outcomes."
Click here to read the original news story.